Press releases

"2024 was one of the best years in the history of Boston Scientific,” said Mike Mahoney, chairman and CEO.

Data sets for two clinical trials show positive results for both FARAPULSE pulsed field ablation and the WATCHMAN device for treating Afib.

Bolt Medical acquisition to expand cardiovascular portfolio, furthering Boston Scientific strategy to address coronary and peripheral artery disease.

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...